Infant Lung Function in Cystic Fibrosis: A Real-World Study

Area of Science:

• Pediatric Pulmonology
• Cystic Fibrosis Research
• Infant Lung Function Assessment

Background:

• Lung function abnormalities are frequently observed in infants with cystic fibrosis (IwCF).
• Limited real-world data exists on the clinical significance of these abnormalities in IwCF.
• Understanding early lung function changes is crucial for timely intervention in IwCF.

Purpose of the Study:

• To investigate the prevalence of lung function abnormalities in infants with cystic fibrosis.
• To assess the correlation between lung function test results and clinical management decisions in IwCF.
• To analyze the impact of microbiology and clinical findings on treatment adjustments in IwCF.

Main Methods:

• Retrospective analysis of infant lung function data from IwCF (2012-2018) at a single center.
• Lung function tests (SF₆ Lung Clearance Index [LCI], FRC, FEV_0.5) performed at 3 months, 1 year, and 2 years.
• Analysis of microbiology, antibiotic prescriptions, and clinical management changes around lung function assessments.

Main Results:

• Lung function abnormalities (elevated zLCI) were present in 31% of 3-month-olds, 28% of 1-year-olds, and 19% of 2-year-olds.
• In cases with positive microbiology or abnormal chest findings, 100% of those with abnormal lung function and 86% with normal lung function received antibiotic prescriptions or management changes.
• Management changes occurred in only 12% of cases with abnormal lung function but normal clinical findings.

Conclusions:

• Clinical management in infants with cystic fibrosis is predominantly driven by clinical findings rather than solely by lung function test results.
• Abnormal lung function (elevated FRC or LCI) had a marginal influence on clinical management decisions in this real-world cohort.
• Further research is needed to optimize the integration of lung function data into clinical decision-making for IwCF.